Pfizer Inc. has beaten back a challenge to a new diabetes treatment that allows sufferers to administer insulin without using injections.

Southern District of New York Judge Leonard Sand, in Novo Nordisk v. Pfizer, 06 Civ. 5819, Thursday refused to grant a preliminary injunction against the drug Exubera, due to be launched in March 2007.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]